Biologic therapy for uveitis

Expert Review of Ophthalmology

Volumn 5, Issue 2, 2010, Pages 225-239

  Hemmati, Houman D ^a   Dunn, James P ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adalimumab; Anakinra; Biologics; Daclizumab; Etanercept; Infliximab; Interferon; Interleukin; Ocular inflammation; TNF; Tumor necrosis factor; Uveitis

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; AZATHIOPRINE; CD20 ANTIGEN; CD52 ANTIGEN; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; DEXAMETHASONE; ETANERCEPT; FLUOCINOLONE ACETONIDE; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 2; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; METHOTREXATE; MYCOPHENOLIC ACID; PLACEBO; PREDNISONE; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BEHCET DISEASE; BIOLOGICAL THERAPY; BONE MARROW SUPPRESSION; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; DEPRESSION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TARGETING; DRUG WITHDRAWAL; ESOPHAGUS CANCER; FATIGUE; FLU LIKE SYNDROME; GUILLAIN BARRE SYNDROME; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFECTION; INFERTILITY; INJECTION SITE REACTION; KIDNEY DISEASE; LUNG EMBOLISM; LUPUS LIKE SYNDROME; LYMPHOCYTOPENIA; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RESEARCH; MELANOMA; METASTASIS; METHODOLOGY; MULTIPLE SCLEROSIS; OFF LABEL DRUG USE; OPTIC NEURITIS; PANCYTOPENIA; PARADOXICAL DRUG REACTION; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REMISSION; RETINA MACULA CYSTOID EDEMA; RETINOPATHY; REVIEW; SIDE EFFECT; STOMACH CANCER; TREATMENT OUTCOME; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; UVEITIS; VISUAL ACUITY; VITREOUS HEMORRHAGE;

EID: 77951645362     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/eop.10.6     Document Type: Review

References (154)

1. Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 111(3), 491-500; discussion 500 (2004).
2. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am. J. Ophthalmol. 140(3), 509-516 (2005).
3. Deschenes J, Murray PI, Rao NA, Nussenblatt RB. International Uveitis Study Group (IUSG): clinical classifcation of uveitis. Ocul. Immunol. Infamm. 16(1), 1-2 (2008).
4. Yeh S, Faia LJ, Nussenblatt RB. Advances in the diagnosis and immunotherapy for ocular infammatory disease. Semin. Immunopathol. 30(2), 145-164 (2008).
5. Anglade E, Whitcup SM. The diagnosis and management of uveitis. Drugs 49 (2), 213-223 (1995).
6. Song J. Systemic management of posterior uveitis. J. Ocul. Pharmacol. Ther. 19(4), 325-343 (2003).
7. Cunningham MA, Edelman JL, Kaushal S. Intravitreal steroids for macular edema: the past, the present, and the future. Surv. Ophthalmol. 53(2), 139-149 (2008).
8. Mohammad DA, Sweet BV, Elner SG Retisert: Is the New Advance in Treatment of Uveitis A Good One? Ann. Pharmacother. 41(3), 449-454 (2007).
9. Hemmati HD, Robin AL. Update on steroid-induced glaucoma. Glaucoma Today 6(4), 24-26 (2008).
10. Jaffe GJ, Martin D, Callanan D, et al Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 113(6), 1020-1027 (2006).
11. Bollinger KE, Smith SD. Prevalence and management of elevated intraocular pressure after placement of an intravitreal sustained-release steroid implant. Curr. Opin. Ophthalmol. 20(2), 99-103 (2009).
12. Jabs DA, Rosenbaum JT. Guidelines for the use of immunosuppressive drugs in patients with ocular infammatory disorders: recommendations of an expert panel. Am. J. Ophthalmol. 131(5), 679 (2001).
13. Galor A, Jabs DA, Leder HA, et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular infammation. Ophthalmology 115(10), 1826-1832 (2008).
14. Kim EC, Foster CS. Immunomodulatory therapy for the treatment of ocular infammatory disease: evidence-based medicine recommendations for use. Int. Ophthalmol. Clin. 46(2), 141-164 (2006).
15. Pacheco PA, Taylor SR, Cuchacovich MT, Diaz GV. Azathioprine in the management of autoimmune uveitis. Ocul. Immunol. Infamm. 16(4), 161-165 (2008).
16. Pasadhika S, Kempen JH, Newcomb CW, et al. Azathioprine for ocular infammatory diseases. Am. J. Ophthalmol. 148(4), 500-509.e2 (2009).
17. Munoz-Fernandez S, Garcia-Aparicio AM, Hidalgo MV, et al. Methotrexate: an option for preventing the recurrence of acute anterior uveitis. Eye 23(5), 1130-1133 (2009).
18. Thorne JE, Jabs DA, Qazi FA, et al. Mycophenolate mofetil therapy for infammatory eye disease. Ophthalmology 112(8), 1472-1477 (2005).
19. Sobrin L, Christen W, Foster CS. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. Ophthalmology 115(8), 1416-1421, 1421.e1 (2008).
20. Neff RT, Hurst FP, Falta EM, et al. Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. Transplantation 86(10), 1474-1478 (2008).
21. Liu J. FK506 and cyclosporin, molecular probes for studying intracellular signal transduction. Immunol. Today 14(6), 290-295 (1993). (Pubitemid 23186993)
22. Hogan AC, McAvoy CE, Dick AD, Lee RW. Long-term effcacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology 114(5), 1000-1006 (2007).
23. Murphy CC, Greiner K, Plskova J, et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch. Ophthalmol. 123(5), 634-641 (2005).
24. Dunn JP. Review of immunosuppressive drug therapy in uveitis. Curr. Opin. Ophthalmol. 15(4), 293-298 (2004).
25. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular infammatory disorders: recommendations of an expert panel. Am. J. Ophthalmol. 130(4), 492-513 (2000).
26. Kempen JH, Gangaputra S, Daniel E, et al Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular infammation: a critical assessment of the evidence. Am. J. Ophthalmol. 146(6), 802-812.e1 (2008).
27. Kempen JH, Daniel E, Dunn JP, et al. Overall and cancer related mortality among patients with ocular infammation treated with immunosuppressive drugs: retrospective cohort study. Br. Med. J. 339, 88-92 (2009).
28. Miserocchi E, Baltatzis S, Ekong A, Roque M, Foster CS. Effcacy and safety of chlorambucil in intractable noninfectious uveitis: the Massachusetts Eye and Ear Infrmary experience. Ophthalmology 109(1), 137-142 (2002).
29. Akpek EK, Jabs DA, Tessler HH, Joondeph BC, Foster CS. Successful treatment of serpiginous choroiditis with alkylating agents. Ophthalmology 109(8), 1506-1513 (2002).
30. Davatchi F, Baygan F, Chams H, Chams C. Cyclophosphamide in the treatment of the ocular manifestations of Behçet's disease. J. Rheumatol. 11(3), 404-405 (1984).
31. Fang W, Yang P. Vogt-Koyanagi-Harada syndrome. Curr. Eye Res. 33(7), 517-523 (2008).
32. Siegel CA, Sands BE. Review article: practical management of infammatory bowel disease patients taking immunomodulators. Aliment Pharmacol. Ther. 22(1), 1-16 (2005).
33. Wallace CA. Current management of juvenile idiopathic arthritis. Best Pract. Res. Clin. Rheumatol. 20(2), 279-300 (2006).
34. Barrie A, Regueiro M. Biologic therapy in the management of extraintestinal manifestations of infammatory bowel disease. Infamm. Bowel Dis. 13(11), 1424-1429 (2007). (Pubitemid 350206857)
35. Lovell DJ. Update on treatment of arthritis in children: new treatments, new goals. Bull. NYU Hosp. Jt. Dis. 64(1-2), 72-76 (2006).
36. Ilowite NT. Update on biologics in juvenile idiopathic arthritis. Curr. Opin. Rheumatol. 20(5), 613-618 (2008).
37. Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr. Opin. Ophthalmol. 18(6), 481-486 (2007).
38. Imrie FR, Dick AD. Nonsteroidal drugs for the treatment of noninfectious posterior and intermediate uveitis. Curr. Opin. Ophthalmol. 18(3), 212-219 (2007).
39. Lim L, Suhler EB, Smith JR. Biologic therapies for infammatory eye disease. Clin. Experiment. Ophthalmol. 34(4), 365-374 (2006).
40. Michalova K, Lim L. Biologic agents in the management of infammatory eye diseases. Curr. Allergy Asthma Rep. 8(4), 339-347 (2008).
41. Deuter CM, Kotter I, Wallace GR, et al. Behçet's disease: ocular effects and treatment. Prog. Retin. Eye Res. 27(1), 111-136 (2008).
42. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 117(2), 244-279 (2008).
43. Dick AD, Forrester J V, Liversidge J, Cope A P. The role of tumour necrosis factor (TNF-a) in experimental autoimmune uveoretinitis (EAU). Prog. Retin. Eye Res. 23(6), 617-637 (2004).
44. Nakamura S, Yamakawa T, Sugita M, et al. The role of tumor necrosis factor-a in the induction of experimental autoimmune uveoretinitis in mice. Invest. Ophthalmol. Vis. Sci. 35(11), 3884-3889 (1994).
45. Okada AA, Sakai J, Usui M, Mizuguchi J. Intraocular cytokine quantifcation of experimental autoimmune uveoretinitis in rats. Ocul. Immunol. Infamm. 6(2), 111-120 (1998). (Pubitemid 28380075)
46. Dick AD, Duncan L, Hale G, Waldmann H, Isaacs J. Neutralizing TNF-a activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis. J. Autoimmun. 11(3), 255-264 (1998).
47. O'Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol. Rev. 226, 10-18 (2008).
48. Diamantstein T, Osawa H. The interleukin-2 receptor, its physiology and a new approach to a selective immunosuppressive therapy by anti-interleukin-2 receptor monoclonal antibodies. Immunol. Rev. 92, 5-27 (1986).
49. Nussenblatt RB. Bench to bedside: new approaches to the immunotherapy of uveitic disease. Int. Rev. Immunol. 21(2-3), 273-289 (2002).
50. Hanlon AM, Jang S, Salgame P. Signaling from cytokine receptors that affect Th1 responses. Front. Biosci. 7, d1247-d1254 (2002).
51. Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J. Cross-regulation of TNF and IFN-a in autoimmune diseases. Proc. Natl Acad. Sci. USA 102(9), 3372-3377 (2005).
52. Bartee E, Mohamed MR, McFadden G. Tumor necrosis factor and interferon: cytokines in harmony. Curr. Opin. Microbiol. 11(4), 378-383 (2008).
53. Luger D, Caspi RR. New perspectives on effector mechanisms in uveitis. Semin. Immunopathol. 30(2), 135-143 (2008).
54. Plskova J, Greiner K, Muckersie E, Duncan L, Forrester JV. Interferon-a: a key factor in autoimmune disease? Invest. Ophthalmol. Vis. Sci. 47(9), 3946-3950 (2006).
55. Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon a-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study. Arch. Dermatol. 138(4), 467-471 (2002).
56. Plskova J, Greiner K, Forrester JV. Interferon-a as an effective treatment for noninfectious posterior uveitis and panuveitis. Am. J. Ophthalmol. 144(1), 55-61 (2007).
57. Theodossiadis PG, Markomichelakis NN, Sfkakis PP. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular infammation. Retina 27(4), 399-413 (2007).
58. Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol. Immunol. 30(16), 1443-1453 (1993).
59. Maini R, St Clair EW, Breedveld F, et al. Infiximab (chimeric anti-tumour necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. ATTRACT Study Group. Lancet 354(9194), 1932-1939 (1999).
60. Sands BE, Anderson FH, Bernstein CN, et al. Infiximab maintenance therapy for fstulizing Crohn's disease. N. Engl. J. Med. 350(9), 876-885 (2004).
61. Sfkakis PP. Behçet's disease: a new target for anti-tumour necrosis factor treatment. Ann. Rheum. Dis. 61(Suppl. 2), ii51-ii53 (2002).
62. Sfkakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infiximab on sight-threatening panuveitis in Behçet's disease. Lancet 358(9278), 295-296 (2001).
63. Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J, Schlincker A, Martin-Mola E. Effect of infiximab on sight-threatening panuveitis in Behçet's disease. Lancet 358(9293), 1644 (2001).
64. Sfkakis PP, Kaklamanis PH, Elezoglou A, et al. Infiximab for recurrent, sight-threatening ocular infammation in Adamantiades-Behçet disease. Ann. Intern. Med. 140(5), 404-406 (2004).
65. Joseph A, Raj D, Dua HS, et al. Infiximab in the treatment of refractory posterior uveitis. Ophthalmology 110(7), 1449-1453 (2003).
66. Arayssi T, Hamra R, Homeidan F, et al. The effcacy of a single dose of infiximab in the treatment of Behçet's disease uveitis. Clin. Exp. Rheumatol. 23(3), 427 (2005).
67. Lindstedt EW, Baarsma GS, Kuijpers RW, van Hagen PM. Anti-TNF-a therapy for sight threatening uveitis. Br. J. Ophthalmol. 89(5), 533-536 (2005).
68. Benitez-del-Castillo JM, Martinez-de-la-Casa JM, Pato-Cour E, et al. Long-term treatment of refractory posterior uveitis with anti-TNF a (infiximab). Eye 19(8), 841-845 (2005).
69. Ohno S, Nakamura S, Hori S, et al. Effcacy, safety, and pharmacokinetics of multiple administration of infiximab in Behçet's disease with refractory uveoretinitis. J. Rheumatol. 31(7), 1362-1368 (2004).
70. Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Effcacy of infiximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial. Arthritis. Rheum. 52(8), 2478-2484 (2005).
71. Accorinti M, Pirraglia MP, Paroli MP, et al. Infiximab treatment for ocular and extraocular manifestations of Behçet's disease. Jpn. J. Ophthalmol. 51(3), 191-196 (2007).
72. Yamada Y, Sugita S, Tanaka H, et al. Comparison of infiximab versus cyclosporine during the initial 6-month treatment period in Behçet's disease. Br. J. Ophthalmol. (2009) (Epub ahead of print).
73. Rosenbaum JT. Blind insight: eyeing anti-tumor necrosis factor treatment in uveitis associated with Behçet's disease. J. Rheumatol. 31(7), 1241-1243 (2004).
74. Petty RE, Southwood TR, Baum J, et al. Revision of the proposed classifcation criteria for juvenile idiopathic arthritis: Durban, 1997. J. Rheumatol. 25(10), 1991-1994 (1998).
75. Petty RE, Southwood TR, Manners P, et al International League of Associations for Rheumatology Classifcation of Juvenile Idiopathic Arthritis: Second Revision, Edmonton, 2001. J. Rheumatol. 31(2), 390-392 (2004).
76. Carvounis PE, Herman DC, Cha S, Burke JP. Incidence and outcomes of uveitis in juvenile rheumatoid arthritis, a synthesis of the literature. Graefes Arch. Clin. Exp. Ophthalmol. 244(3), 281-290 (2006).
77. Kahn P, Weiss M, Imundo LF, Levy DM. Favorable response to high-dose infiximab for refractory childhood uveitis. Ophthalmology 113(5), 860-864.e2 (2006).
78. Rajaraman RT, Kimura Y, Li S, Haines K, Chu DS. Retrospective case review of pediatric patients with uveitis treated with infiximab. Ophthalmology 113(2), 308-314 (2006).
79. Richards JC, Tay-Kearney ML, Murray K, Manners P. Infiximab for juvenile idiopathic arthritis-associated uveitis. Clin. Exp. Ophthalmol. 33(5), 461-468 (2005).
80. Sharma SM, Ramanan AV, Riley P, Dick AD. Use of infiximab in juvenile onset rheumatological disease-associated refractory uveitis: effcacy in joint and ocular disease. Ann. Rheum. Dis. 66(6), 840-841 (2007).
81. Murphy CC, Ayliffe WH, Booth A, et al. Tumor necrosis factor a blockade with infiximab for refractory uveitis and scleritis. Ophthalmology 111(2), 352-356 (2004).
82. El-Shabrawi Y, Hermann J. Anti-tumor necrosis factor-a therapy with infiximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology 109(12), 2342-2346 (2002).
83. El-Shabrawi Y, Hermann J. Anti-TNF a therapy in chronic necrotizing scleritis resistant to standard immunomodulatory therapy in a patient with Wegener's granulomatosis. Eye 19(9), 1017-1018 (2005).
84. Markomichelakis NN, Theodossiadis PG, Pantelia E, et al. Infiximab for chronic cystoid macular edema associated with uveitis. Am. J. Ophthalmol. 138(4), 648-650 (2004).
85. Garrity JA, Coleman AW, Matteson EL, Eggenberger ER, Waitzman DM. Treatment of recalcitrant idiopathic orbital infammation (chronic orbital myositis) with infiximab. Am. J. Ophthalmol. 138(6), 925-930 (2004).
86. Wang Y, Gaudio PA. Infiximab therapy for 2 patients with Vogt-Koyanagi-Harada syndrome. Ocul. Immunol. Infamm. 16(4), 167-171 (2008).
87. Sobrin L, Kim EC, Christen W, et al Infiximab therapy for the treatment of refractory ocular infammatory disease. Arch. Ophthalmol. 125(7), 895-900 (2007).
88. Lopez-Gonzalez R, Loza E, Jover JA, et al Treatment of refractory posterior uveitis with infiximab: a 7-year follow-up study. Scand. J. Rheumatol. 38(1), 58-62 (2009).
89. Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infiximab therapy for refractory uveitis: preliminary safety and effcacy outcomes. Arch. Ophthalmol 123(7), 903-912 (2005).
90. Suhler EB, Smith JR, Giles TR, et al Infiximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch. Ophthalmol. 127(6), 819-822 (2009).
91. Goldstein DA. Uncovering the risks of immunosuppressive therapy in patients with uveitis. Arch. Ophthalmol. 127(6), 799-800 (2009).
92. Rudwaleit M, Rodevand E, Hokck P, et al. Adalimumab effectively reduces the rate of anterior uveitis fares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann. Rheum. Dis. 68(5), 696-701 (2009).
93. Vazquez-Cobian LB, Flynn T, Lehman TJ. Adalimumab therapy for childhood uveitis. J. Pediatr. 149(4), 572-575 (2006).
94. Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br. J. Ophthalmol. 91(3), 319-324 (2007).
95. Mushtaq B, Saeed T, Situnayake RD, Murray PI. Adalimumab for sight-threatening uveitis in Behçet's disease. Eye 21(6), 824-825 (2007).
96. Dhingra N, Morgan J, Dick AD. Switching biologic agents for uveitis. Eye 23(9), 1868-1870 (2009).
97. Peppel K, Crawford D, Beutler B. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J. Exp. Med. 174(6), 1483-1489 (1991).
98. Smith BJ, McMillan VM, Newton JS. Corticosteroid-sparing effect of etanercept in idiopathic panuveitis resistant to immunosuppressive therapy. J. Clin. Rheumatol. 7(3), 175-178 (2001).
99. Reiff A, Takei S, Sadeghi S, et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis. Rheum. 44(6), 1411-1415 (2001).
100. Foster CS, Tufail F, Waheed NK, et al. Effcacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch. Ophthalmol. 121(4), 437-440 (2003).
101. Smith JA, Thompson DJ, Whitcup SM, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis. Rheum. 53(1), 18-23 (2005).
102. Schmeling H, Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology (Oxford) 44(8), 1008-1011 (2005).
103. Paridaens D, van den Bosch WA, van der Loos TL, Krenning EP, van Hagen PM. The effect of etanercept on Graves' ophthalmopathy: a pilot study. Eye 19(12), 1286-1289 (2005).
104. Baughman RP, Lower EE, Bradley DA, Raymond LA, Kaufman A. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 128(2), 1062-11047 (2005).
105. Tynjala P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K. Infiximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann. Rheum. Dis. 66(4), 548-550 (2007).
106. Foeldvari I, Nielsen S, Kummerle-Deschner J, et al. Tumor necrosis factor-a blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J. Rheumatol. 34(5), 1146-1150 (2007).
107. Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infiximab and etanercept. Arthritis. Rheum. 52(8), 2447-2451 (2005).
108. Galor A, Perez VL, Hammel JP, Lowder CY. Differential effectiveness of etanercept and infiximab in the treatment of ocular infammation. Ophthalmology 113(12), 2317-2323 (2006).
109. Elewaut D, Matucci-Cerinic M. Treatment of ankylosing spondylitis and extraarticular manifestations in everyday rheumatology practice. Rheumatology (Oxford) 48(9), 1029-1035 (2009).
110. Simsek I, Erdem H, Pay S, Sobaci G, Dinc A. Optic neuritis occurring with anti-tumour necrosis factor a therapy. Ann. Rheum. Dis. 66(9), 1255-1258 (2007).
111. Lim LL, Fraunfelder FW, Rosenbaum JT Do tumor necrosis factor antagonists cause uveitis? A registry-based study. Arthritis. Rheum. 56, 3248-3252 (2008).
112. Fouache D, Goeb V, Massy-Guillemant N, et al. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyoloarthropathies: a retrospective study. Rheumatology 48(7), 761-764 (2009).
113. Cordero-Coma M, Benito MF, Hernanez AM, Antolin SC, Ruiz JMG. Serpiginous choroiditis. Am. J. Ophthalmol. 115(9), 1633-1634 (2008).
114. Gupta V, Gupta A, Arora S. Presumed tubercular serpiginouslike choroiditis: clinical presentations and management. Ophthalmology 110, 1744-1749 (2007).
115. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. J. Am. Med. Assoc. 295(19), 2275-2285 (2006).
116. Hwang WY, Foote J. Immunogenicity of engineered antibodies. Methods 36(1), 3-10 (2005).
117. Baert F, Noman M, Vermeire S, et al. Infuence of immunogenicity on the long-term effcacy of infiximab in Crohn's disease. N. Engl. J. Med. 348(7), 601-608 (2003).
118. Radstake TR, Svenson M, Eijsbouts AM, et al. Formation of antibodies against infiximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann. Rheum. Dis. 68(11), 1739-1745 (2008).
119. Allaart CF, Breedveld FC, Dijkmans BA. Treatment of recent-onset rheumatoid arthritis: lessons from the BEST Study. J. Rheumatol. Suppl. 80, 25-33 (2007).
120. Zhang R, Qian J, Guo J, Yuan YF, Xue K. Suppression of experimental autoimmune uveoretinitis by anti-IL-17 antibody. Curr. Eye Res. 34(4), 297-303 (2009).
121. Wohlrab J, Fischer M, Taube KM, Marsch WC. Treatment of recalcitrant psoriasis with daclizumab. Br. J. Dermatol. 144(1), 209-210 (2001).
122. Rose J W, Burns JB, Bjorklund J, et al. Daclizumab Phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 69(8), 785-789 (2007).
123. Nussenblatt RB, Fortin E, Schiffman R, et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a Phase I/II clinical trial. Proc. Natl Acad. Sci. USA 96(13), 7462-7466 (1999).
124. Nussenblatt RB, Thompson DJ, Li Z, et al. Humanized anti-interleukin-2 (IL-2) receptor a therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J. Autoimmun. 21(3), 283-293 (2003).
125. Buggage RR, Levy-Clarke G, Sen HN, et al. A double-masked, randomized study to investigate the safety and effcacy of daclizumab to treat the ocular complications related to Behçet's disease. Ocul. Immunol. Infamm. 15(2), 63-70 (2007).
126. Papaliodis GN, Chu D, Foster CS. Treatment of ocular infammatory disorders with daclizumab. Ophthalmology 110(4), 786-789 (2003).
127. Sobrin L, Huang JJ, Christen W, et al. Daclizumab for treatment of birdshot chorioretinopathy. Arch. Ophthalmol. 126(2), 186-191 (2008).
128. Gallagher M, Quinones K, Cervantes-Castaneda RA, Yilmaz T, Foster CS. Biological response modifer therapy for refractory childhood uveitis. Br. J. Ophthalmol. 91(10), 1341-1344 (2007).
129. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N. Engl. J. Med. 338(3) 161-165 (1998). (Pubitemid 28041863)
130. Bumgardner GL, Hardie I, Johnson RW, et al. Results of 3-year Phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Transplantation 72(5), 839-845 (2001).
131. Botsios C, Sfriso P, Ostuni PA, Todesco S, Punzi L. Effcacy of the IL-1 receptor antagonist, anakinra, for the treatment of diffuse anterior scleritis in rheumatoid arthritis. Report of two cases. Rheumatology (Oxford) 46(6), 1042-1043 (2007).
132. Teoh SC, Sharma S, Hogan A, et al. Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome. Br. J. Ophthalmol. 91(2), 263-264 (2007).
133. Reiff A. The use of anakinra in juvenile arthritis. Curr. Rheumatol. Rep. 7(6), 434-440 (2005).
134. Fleischmann RM, Tesser J, Schiff MH, et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann. Rheum. Dis. 65(8), 1006-1012 (2006). (Pubitemid 44133261)
135. Cui Y, Shao H, Sun D, Kaplan HJ. Regulation of interphotoreceptor retinoid-binding protein (IRBP)-specifc Th1 and Th17 cells in anterior chamber-associated immune deviation (ACAID). Invest. Ophthalmol. Vis. Sci. 50(12), 5811-5817 (2009).
136. Jiang G, Ke Y, Sun D, Han G, Kaplan HJ, Shao H. Reactivation of uveitogenic T cells by retinal astrocytes derived from experimental autoimmune uveitis-prone B10RIII mice. Invest. Ophthalmol. Vis. Sci. 49(1), 282-289 (2008).
137. Liu X, Yang P, Lin X, et al. Inhibitory effect of cyclosporin A and corticosteroids on the production of IFN-g and IL-17 by T cells in Vogt-Koyanagi-Harada syndrome. Clin. Immunol. 131(2), 333-342 (2009).
138. Gueudry J, Wechsler B, Terrada C, et al Long-term effcacy and safety of low-dose interferon a2a therapy in severe uveitis associated with Behçet disease. Am. J. Ophthalmol. 147(6), 1109-1110 (2008).
139. Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M. Results of interferon-a therapy in patients with Behçet uveitis. Graefes Arch. Clin. Exp. Ophthalmol 244(12), 1692-1695 (2006).
140. Onal S, Kazokoglu H, Direskeneli H, Yavuz S. Low-dose interferon a-2a in severe uveitis associated with Behçet disease. Am. J. Ophthalmol. 147(6), 1109-1119 (2009).
141. Krause L, Altenburg A, Pleyer U, et al Long-term visual prognosis of patients with ocular Adamantiades-Behçet's disease treated with interferon-a-2a. J. Rheumatol. 35(5), 896-903 (2008).
142. Bodaghi B, Gendron G, Wechsler B, et al. Effcacy of interferon a in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br. J. Ophthalmol. 91(3), 335-339 (2007).
143. Deuter CM, Koetter I, Gunaydin I, et al Effcacy and tolerability of interferon a treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br. J. Ophthalmol. 93(7), 906-913 (2006).
144. Touitou V, Sene D, Fardeau C, et al Interferon-a2a and Vogt-Koyanagi-Harada disease: a double-edged sword? Int. Ophthalmol. 27(2-3), 211-215 (2007).
145. Mackensen F, Max R, Becker MD. Interferon therapy for ocular disease. Curr. Opin. Ophthalmol. 17(6), 567-573 (2006).
146. Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infiximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann. Intern. Med. 146(9), 621-630 (2007).
147. Tynjala P, Vahasalo P, Honkanen V, Lahdenne P. Drug survival of the frst and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis. Ann. Rheum. Dis. 68, 552-557 (2009).
148. Jabs DA, Mudun A, Dunn JP, Marsh MJ. Episcleritis and scleritis: clinical features and treatment results. Am. J. Ophthalmol 130(4), 469-476 (2000).
149. Mitoma H, Horiuchi T, Tsukamoto H, et al. Mechanisms for cytotoxic effects of anti-tumour necrosis factor agents on transmembrane tumor necrosis factor aexpressing cells: comparison among infiximab, etanercept, and adalimumab. Arthritis. Rheum. 58, 1248-1257 (2008).
150. Angeles-Han S, Flynn T, Lehman T. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis-a case report. J. Rheumatol. 35(9), 1897-1898 (2008).
151. Tugal-Tutkun I, Ayranci O, Kasapcopur O, Kir N. Retrospective analysis of children with uveitis treated with infiximab. J. AAPOS 12(6), 611-613 (2008).
152. Simonini G, Zannin ME, Caputo R, et al. Loss of effcacy during long-term infiximab therapy for sight-threatening childhood uveitis. Rheumatology (Oxford) 47(10), 1510-1514 (2008).
153. Carson KR, Focosi D, Major EO Monoclonal Antibody-associated Progressive Multifocal Leucoencephalopathy in Patients Treated with Rituximab, Natalizumab, and Efalizumab: A Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol. 10(8), 816-824 (2009).
154. Theodossiadis PG, Liakakos VS, Sfkakis PP, Vergados IA, Theodossiadis GP. Intravitreal administration of the anti-tumor necrosis factor agent infiximab for neovascular age-related macular degeneration. Am. J. Ophthalmol. 147(5), 761-763 (2008).